Introduction
The transition from androgen-dependent to androgenindependent growth during prostate cancer progression is of great concern, since androgen-independent tumours are incurable. One possible mechanism underlying this transition is a switch from androgens to growth factors as primary regulators of prostate cancer cell proliferation. Fibroblast growth factors (FGFs), insulin-like growth factors (IGFs) and epidermal growth factor (EGF) are examples of autocrine factors which stimulate growth of advanced, androgen-independent, prostate cancer (Russell et al., 1998) . For EGF, binding of the ligand to the receptor induces cell proliferation by activating well-characterized signal transduction pathways that involve phosphorylation and activation of mitogen-activated protein kinases (MAPKs). The activation of the GTP-ase Ras is one of the initial steps in EGF signalling, and once Ras is activated, it can facilitate activation of the serine/threonine kinase Raf, PI3-kinase and Ral-GEF, a guanine nucleotide exchange factor that activates the small GTP-ase Ral (reviewed by Pruitt and Der, 2001) . Activated Ral binds to RalBP1, which exhibits GAP (GTPase-activating protein) activity towards Cdc42 and Rac (Cantor et al., 1995; Jullien-Flores et al., 1995; Park and Weinberg, 1995) . REPS2/POB1 is a protein partner of RalBP1, contains a single EH domain, two SH3 binding sites and several other functional regions (Ikeda et al., 1998) . REPS2/POB1 has been implicated in endocytosis and signal transduction (Ikeda et al., 1998; Nakashima et al., 1999; Kariya et al., 2000) and is currently evaluated for its putative role in prostate cancer progression.
Endogenous expression of REPS2/POB1 in prostate cancer cell lines
In a previous study, reduced mRNA expression of REPS2/POB1 was found in the androgen-independent human prostate cancer cell lines PC3, DU145 and LNCaP-LNO, as compared to the expression level in the androgen-dependent LNCaP-FGC cell line. In addition, using a panel of human prostate cancer xenografts, REPS2/POB1 expression was also found to be markedly reduced in androgen-independent prostate cancer xenografts (Chang et al., 1997) .
Using a hypothalamus cDNA library, a 1987 bp cDNA clone was obtained containing an open reading frame encoding a protein of 659 amino-acid residues. This protein consists of the published coding region of REPS2/POB1 (accession number AF010233) minus one glutamine at position 43, and 139 additional amino-acid residues at the NH 2 -terminal end ( Figure 1a ). All reported studies so far, however, made use of the shorter 521 amino-acid REPS2/POB1 protein. We examined the possible translation of the extended REPS2/POB1 protein in human cells using a specific REPS2/POB1 antibody and were able to detect 78 and 58 kDa protein bands in lysates from prostate cancer cell lines (Figure 1b) . These results indicate that both the 659 amino-acid residue and the 521 amino-acid residue REPS2/POB1 protein are expressed in these cell lines.
Another argument in favour of the coexistence of a longer REPS2/POB1 protein, is the observation that the translation start sequence, proposed by Kozak (1987) , is more consistent with the sequence around the more 5 0 ATG, described herein, than the translation start sequence of REPS2/POB1 described by Ikeda et al. (1998) (Figure 2a) . Furthermore, the additional 139 NH 2 -terminal amino-acid residues form a putative second EH domain ( Figure 2b ) and this amino-acid sequence exhibits high homology with the mouse Reps1 and human REPS1 proteins (72% identity). Whether both REPS2/POB1 products are formed by alternative first ATG usage or alternative pre-mRNA splicing is currently unknown.
We observed a good correlation between mRNA and protein expression of REPS2/POB1 in DU145, PC3, LNCaP-FGC and LNCaP-LNO cells. The LNCaP-FGC cells were found to express REPS2/POB1 mRNA and protein at relatively high levels, whereas LNCaP-LNO and DU145 cells do not express detectable levels of REPS2/POB1 mRNA and protein. The PC3 cells 
Role of REPS2/POB1 in signal transduction: apoptosis
To determine the cellular localization of REPS2/POB1 in prostate cancer cells, LNCaP-FGC and LNCaP-LNO cells were transiently transfected with cDNA encoding REPS2/POB1 or REPS2/POB1 (140-659) fused to GFP. Cells were analysed with fluorescence microscopy at different time points after transfection. It was observed that both variants of REPS2/POB1 mainly reside in the cytosol and not in the nucleus (Figure 3a) . Subsequently, the cells were subjected to prolonged expression of GFP-tagged REPS2/POB1, REPS2/POB1 (140-659) or part of the androgen receptor (AR), to examine the effect of REPS2/POB1 and REPS2/POB1 (140-659) on prostate cancer cell growth. The tagged AR was used to evaluate nonspecific effects of the transfection procedure. REPS2/POB1 was found to induce programmed cell death. Transfected cells that showed DNA fragmentation and cell membrane damage, as observed using Hoechst and propidium iodide staining, were considered to be apoptotic (Figure 3b-d) . REPS2/POB1 (140-659) or REPS2/POB1-induced apoptosis in 45% of transfected cells already within 48 h and up to 60% after 96 h (Figure 3e ). Based on these observations, a regulating role for REPS2/POB1 in a signalling pathway that controls apoptosis was hypothesized.
We investigated whether the role which REPS2/POB1 seems to play in induction of apoptosis can be explained when the function of one of its binding partners, RalBP1, is implicated. When we transfected LNCaP cells with a deletion mutant of REPS2/POB1 lacking the RalBP1 binding domain (1-373), only 30-40% of the transfected cells became apoptotic (72-96 h), while a mutant containing only the RalBP1 binding domain of REPS2/POB1 (451-659) induced apoptosis in 40-75% of the transfected cells (Figure 3f ). Since the expression levels of the two proteins were similar, these observations suggest that the RalBP1 binding properties of REPS2/POB1 are at least partly responsible for apoptosis induction in these cells.
RalBP1 is a protein with GTPase activating protein (GAP) activity towards Rac1 and Cdc42 (Cantor et al., 1995; Jullien-Flores et al., 1995; Park and Weinberg, 1995) . Activated Rac1 and Cdc42 have been implicated in signalling towards cell survival (Joneson and BarSagi, 1999; Osada et al., 1999) and, because of its GAP activity, RalBP1 is capable of inhibiting these functions. The GAP activity of RalBP1, in turn, can be inhibited by activated Ral, which translocates RalPB1 to the cell membrane and physically away from Rac1 and Cdc42 (Matsubara et al., 1997) . The presence of REPS2/POB1, as a cytosolic protein, may in this respect function to counteract activated Ral, maintaining a number of RalBP1 molecules in the cytosol and thus available to inactivate Rac1 and Cdc42. Overexpression of REPS2/ POB1 may result in a strong inhibition of Rac1 and Cdc42 signalling, which may consequently result in the observed induction of apoptosis.
The deletion mutant that lacks the RalBP1 binding domain also induces apoptosis, but less efficient, suggesting that the two EH domains of REPS2/POB1 may also play a role. The C-terminal EH domain of REPS2/POB1 binds to Eps15 and Epsin and is involved in internalization of growth factor receptors (Nakashima et al., 1999) . Disruption of endocytosis might lead to improper signal transduction and consequently to cell death. For example, it has been reported that inhibition of endocytosis of EGF receptors or insulin receptors by a dominant interfering mutant of dynamin results in inhibition of the activation of the protein kinases ERK1 and ERK2, emphasizing the importance of signalling during and after endocytosis (Vieira et al., 1996; Ceresa et al., 1998) . Kozak (1987) . (b) Alignment of several EH domains. REPS2_EH1 is the EH domain found in the first 139 amino-acid residues of REPS2/ POB1. Also presented are: REPS2_EH2: REPS2/POB1 (275-364); Eps15_EH3: Eps15 (218-313); Eps15R_EH: Eps15R (13-103); lnters_EH1: Intersectin2 (28-118) and . Amino acids shared between more than 50% of the EH domains are in italics, between more than 75% are underlined and 100% alignment is shown in bold. All sequences are from human. Sequences were aligned using the DNAMAN program REPS2/POB1 in prostate cancer cells Josien K Oosterhoff et al
Role of REPS2/POB1 in signal transduction: inhibition of signalling
It has been described that Rac1 and Cdc42 are involved in activation of Jun (Coso et al., 1995) and heterodimers of Jun and Fos activate, among others, genes controlled by promoter sequences containing a TPA response element (TRE) (Angel et al., 1987) . A phorbolester responsive reporter system (5 Â TRE luciferase reporter) was used to investigate the effect of transient REPS2/ POB1 expression in the human prostate cancer cell line PC3. The TRE reporter can be activated by several growth factors (including EGF), serum and synthetic compounds like phorbol esters. Since PC3 cells are not very sensitive to EGF (Janssen et al., 1995) , 15% v/v fetal calf serum was used to activate transcription of the luciferase reporter gene. It was observed that luciferase transcription was increased approximately eight-to 12-fold over control expression by addition of serum. Furthermore, short-term transfection (24 h) with increasing amounts of REPS2/POB1 cDNA/well inhibited serum-induced activation of the TRE reporter. Using 10, 30 and 100 ng REPS2/POB1 cDNA/well, a 46, 80 and 90% reduction in luciferase activity was observed, respectively, compared to mock-transfected cells (Figure 4 ). This reduction in luciferase activity was not a result of REPS2/POB1-induced apoptosis and a decreasing cell number, because apoptosis is not observed at 24 h after transfection. Furthermore, in a parallel transfection assay, where a RSV-luciferase reporter was used, no significant inhibition of luciferase activity was observed with increasing amounts of REPS2/POB1 cDNA. These results indicate that overexpression of REPS2/POB1 exerts a marked inhibitory effect on serum-induced signalling to a TRE reporter.
In advanced prostate cancer cells, the expression status of REPS2/POB1 does not represent overexpression, but rather loss of expression. Consequently, the inhibiting activity of RalBP1 on Rac1 and Cdc42 may be compromised, resulting in loss of control of cell survival and consequently mitogenic signalling.
It is concluded that loss of REPS2/POB1 expression, which occurs during progression of prostate cancer, results in dysregulation of growth factor signalling. This can be the result of loss of the interaction of REPS2/ POB1 with RalBP1 or the result of loss of function of REPS2/POB1 during growth factor receptor internalization. Furthermore, it is also possible that both mechanisms simultaneously play a role in REPS2/ POB1-induced dysregulated growth factor signalling. Since RalBP1, like REPS2/POB1, has also been reported to be involved in endocytosis (Jullien-Flores et al., 2000) , effects of REPS2/POB1 on endocytosis, via binding to RalBP1, and then on signal transduction, cannot be excluded. Furthermore, it has been described that dysregulated endocytosis can lead to mitogenic signalling, and that mutation or abnormal expression of endocytic proteins is implicated in tumour development (Floyd and De Camilli, 1998; Di Fiore and Gill, 1999) . Further research utilizing stable inducible cell lines expressing REPS2/POB1 at a more physiological level, will be used to unravel the precise role of REPS2/POB1 in signalling and endocytosis.
Taken all data together, there is evidence to suggest that loss of REPS2/POB1 expression, during progression of prostate cancer, results in loss of control of cell growth signalling. This can be a direct effect through RalBP1 or an indirect effect via a function in growth factor internalization. Further investigations of the role of REPS2/POB1 in control of prostate cancer progression are important to improve our understanding of androgen-independent tumour growth.
